Is Neogen Chemicals overvalued or undervalued?

Valuation Metrics and What They Indicate

Neogen Chemicals’ price-to-earnings (PE) ratio stands at a lofty 86.07, signalling a high premium relative to its earnings. This figure is considerably above the average PE ratios of many companies in the specialty chemicals industry, suggesting that investors are pricing in significant growth expectations. The price-to-book value of 3.80 further indicates that the stock trades well above its net asset value, which is typical for growth-oriented companies but warrants caution if earnings growth does not materialise as expected.

Enterprise value multiples such as EV to EBIT (38.05) and EV to EBITDA (30.31) also reflect a stretched valuation. These multiples are higher than many peers, implying that the market anticipates robust operational performance ahead. However, the company’s return on capital employed (ROCE) and return on equity (ROE) are relatively modest at 5.93% and 4.41% respectively, which raises questions about the efficiency of capital utilisation compared to the valuation premium.

Peer Comparison: Contextualising Neogen’s Valuation

When compared with its industry peers, Neogen Chemicals is classified as expensive but not the most overvalued. For instance, Solar Industries and Gujarat Fluorochemicals are rated very expensive with PE ratios of 91.67 and 57.17 respectively. Meanwhile, companies like Godrej Industries and Atul Chemicals trade at more reasonable valuations, with PE ratios in the mid-30s and low 30s, reflecting more moderate growth expectations or stronger fundamentals.

Neogen’s EV to EBITDA multiple of 30.31 is high but still below some peers such as Solar Industries (56.42) and Acutaas Chemicals (50.40), indicating that while the stock is pricey, it is not the most stretched in the sector. The PEG ratio of zero is unusual and suggests either a lack of reliable earnings growth projections or a data anomaly, which complicates valuation assessment based purely on this metric.

Recent Price Performance and Market Sentiment

Neogen Chemicals has experienced a significant correction over the past year, with a one-year return of -40.63%, starkly contrasting with the Sensex’s positive 7.31% return over the same period. Year-to-date, the stock has declined nearly 48%, indicating considerable investor caution or disappointment. The current price of ₹1,150.75 is closer to its 52-week low of ₹1,118.50 than its 52-week high of ₹2,414.90, reflecting a substantial retracement from previous highs.

This sharp decline may offer a valuation entry point for investors willing to bet on a recovery, but it also signals underlying challenges or market scepticism about the company’s near-term prospects. The low dividend yield of 0.09% further suggests that the company is reinvesting earnings rather than returning cash to shareholders, which is typical for growth companies but adds to risk if growth falters.

Balancing Growth Potential Against Valuation Risks

Neogen Chemicals’ valuation reflects high growth expectations that are not yet fully supported by its current profitability metrics. The modest ROCE and ROE figures suggest that the company has room to improve operational efficiency and capital returns. Investors should weigh the potential for earnings growth against the risk of paying a premium for uncertain future performance.

Moreover, the stock’s recent underperformance relative to the broader market indicates that sentiment has turned cautious, possibly due to sector-specific headwinds or company-specific challenges. While the specialty chemicals industry often commands premium valuations due to its growth prospects and innovation-driven nature, Neogen’s current multiples suggest that much of this optimism is already priced in.

For investors considering Neogen Chemicals, it is crucial to monitor upcoming earnings reports, margin trends, and any strategic initiatives that could enhance profitability and justify the valuation. Until then, the stock appears expensive relative to its current fundamentals, though not excessively so compared to some peers.

Conclusion: Is Neogen Chemicals Overvalued or Undervalued?

In summary, Neogen Chemicals is currently classified as expensive, having moved down from a very expensive valuation grade. Its high PE and EV multiples indicate that the market expects strong growth, but the company’s modest returns on capital and recent share price decline temper enthusiasm. Compared to its peers, Neogen is not the most overvalued but trades at a premium that demands consistent operational improvement and earnings growth.

Given the significant price correction over the past year, some investors might view the current levels as a potential buying opportunity, especially if they believe in the company’s long-term growth story. However, cautious investors may prefer to wait for clearer signs of profitability improvement or explore alternative stocks within the specialty chemicals sector that offer more attractive valuations or stronger fundamentals.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →